617 related articles for article (PubMed ID: 34019713)
41. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Lucas F; Larkin K; Gregory CT; Orwick S; Doong TJ; Lozanski A; Lozanski G; Misra S; Ngankeu A; Ozer HG; Sampath D; Thangavadivel S; Yilmaz SA; Rogers KA; Byrd JC; Woyach JA; Blachly JS
Blood; 2020 Jun; 135(24):2192-2195. PubMed ID: 32232486
[No Abstract] [Full Text] [Related]
42. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
Chen LS; Bose P; Cruz ND; Jiang Y; Wu Q; Thompson PA; Feng S; Kroll MH; Qiao W; Huang X; Jain N; Wierda WG; Keating MJ; Gandhi V
Blood; 2018 Nov; 132(21):2249-2259. PubMed ID: 30254130
[TBL] [Abstract][Full Text] [Related]
43. Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
Ayed AO; Parikh SA
Leuk Lymphoma; 2018 Oct; 59(10):2287-2296. PubMed ID: 29115892
[TBL] [Abstract][Full Text] [Related]
44. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Bartlett NL; Costello BA; LaPlant BR; Ansell SM; Kuruvilla JG; Reeder CB; Thye LS; Anderson DM; Krysiak K; Ramirez C; Qi J; Siegel BA; Griffith M; Griffith OL; Gomez F; Fehniger TA
Blood; 2018 Jan; 131(2):182-190. PubMed ID: 29074501
[TBL] [Abstract][Full Text] [Related]
45. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
46. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A; Utro F; Wang Q; Cha J; Vihinen M; Martindale S; Zhou Y; Ren Y; Tyekucheva S; Kim AS; Fernandes SM; Saksena G; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Lederer JA; Zain R; Smith CIE; Leshchiner I; Parida L; Getz G; Brown JR
Blood Adv; 2023 May; 7(9):1929-1943. PubMed ID: 36287227
[TBL] [Abstract][Full Text] [Related]
47. Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Javidi-Sharifi N; Brown JR
Expert Rev Hematol; 2024 Jun; 17(6):201-210. PubMed ID: 38784995
[TBL] [Abstract][Full Text] [Related]
48. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
[TBL] [Abstract][Full Text] [Related]
49. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
50. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S; Sutton LA; Ljungström V; Capasso A; Pandzic T; Weström S; Foroughi-Asl H; Skaftason A; Gellerbring A; Lyander A; Gandini F; Gaidano G; Trentin L; Bonello L; Reda G; Bödör C; Stavroyianni N; Tam CS; Marasca R; Forconi F; Panayiotidis P; Ringshausen I; Jaksic O; Frustaci AM; Iyengar S; Coscia M; Mulligan SP; Ysebaert L; Strugov V; Pavlovsky C; Walewska R; Österborg A; Cortese D; Ranghetti P; Baliakas P; Stamatopoulos K; Scarfò L; Rosenquist R; Ghia P
Blood Adv; 2023 Jun; 7(12):2794-2806. PubMed ID: 36696464
[TBL] [Abstract][Full Text] [Related]
51. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
[TBL] [Abstract][Full Text] [Related]
52. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.
Zhang D; Harris HM; Chen J; Judy J; James G; Kelly A; McIntosh J; Tenn-McClellan A; Ambing E; Tan YS; Lu H; Gajewski S; Clifton MC; Yung S; Robbins DW; Pirooznia M; Skånland SS; Gaglione E; Mhibik M; Underbayev C; Ahn IE; Sun C; Herman SEM; Noviski M; Wiestner A
Blood; 2023 Mar; 141(13):1584-1596. PubMed ID: 36375120
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
Jebaraj BMC; Müller A; Dheenadayalan RP; Endres S; Roessner PM; Seyfried F; Walliser C; Wist M; Qi J; Tausch E; Mertens D; Fox JA; Debatin KM; Meyer LH; Taverna P; Seiffert M; Gierschik P; Stilgenbauer S
Blood; 2022 Feb; 139(6):859-875. PubMed ID: 34662393
[TBL] [Abstract][Full Text] [Related]
54. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
55. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
Lampson BL; Brown JR
Expert Rev Hematol; 2018 Mar; 11(3):185-194. PubMed ID: 29381098
[TBL] [Abstract][Full Text] [Related]
56. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
[TBL] [Abstract][Full Text] [Related]
57. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Danilov AV; Persky DO
Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
[TBL] [Abstract][Full Text] [Related]
58. A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.
Raghunathan V; Fan G; Kittai AS; Okada C; Danilov AV; Spurgeon SE
Eur J Haematol; 2021 Feb; 106(2):294-297. PubMed ID: 33089525
[TBL] [Abstract][Full Text] [Related]
59. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
[TBL] [Abstract][Full Text] [Related]
60. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
